New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
06:20 EDTGHDXGenomic Health downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded Genomic Health citing lack of catalysts. Price target lowered to $29 from $36.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
08:16 EDTGHDXGenomic Health's Oncotype prostate cancer test issued draft LCD determination
Subscribe for More Information
May 20, 2015
08:08 EDTGHDXGenomic Health's Oncotype prostate cancer risk test shows positive results
Subscribe for More Information
May 18, 2015
08:05 EDTGHDXGenomic Health announces results from study on methods to detect bladder cancer
Genomic Health announced positive results from a second, larger liquid biopsy feasibility study demonstrating the Company's ability to detect tumor-specific DNA in urine, which is expected to enable bladder cancer recurrence monitoring. It is estimated that early-stage bladder cancer recurs in only 10 to 15 percent of patients in the first year, and in more than half of patients over time. However, approximately one-third of all cystoscopies a procedure using a thin instrument equipped with a camera and light to look at the inside of the bladder generate false positive results. Genomic Health and its collaborators used the Company's next-generation sequencing and polymerase chain reaction based platforms and refined methodology to target tumor-specific differential DNA methylation and single nucleotide variations. In the study, researchers identified tumor-specific DNA markers in 94 percent of tissue samples and found a strong association between the same markers in urine. These findings are expected to enable accurate monitoring for cancer recurrence in the urine of early-stage bladder cancer patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use